

## About HOPE-Neuron Therapeutx

HOPE-Neuron Therapeutx is a leading innovator in device-enabled, cell-based therapeutics for the treatment of autoimmune neurodegenerative diseases. The company's initial target is Amyotrophic Lateral Sclerosis (ALS, also known as *Lou Gehrig's Disease*). Following a successful transgenic ALS mouse study that showed highly promising results, the company is now preparing for a pivotal human trial.



Built on decades of research, HOPE-Neuron's **patented non-pharma technology** (SELtx™) activates the body's own immune system to fight disease through immune balancing and healing, anti-inflammation, and the normalization of imbalanced disease cells. Designed as an outpatient therapy utilizing a patient's own blood, SELtx™ represents **a new type of therapy platform** for multiple conditions. We are currently advancing through preclinical and early-stage clinical development, with a goal to initiate human trials for ALS within 12 months of funding. Our regulatory strategy includes fast-track designation and a clear path to FDA engagement.

In addition to ALS, future targets include Alzheimer's, Parkinson's, MS (multiple sclerosis), cancer, and other autoimmune-related diseases. Our mission is to bring safe, effective, and accessible therapies to patients via our novel therapeutic process, which has shown the ability to counter the root cause of autoimmune dysfunction.

HOPE-Neuron is based in the United States, has conducted animal studies at the Indiana University School of Medicine, and plans to conduct initial human trials at the Barrow Neurological Institute in Arizona.

**For investor inquiries, media requests, or partnership opportunities, please contact our VP of Business Development, Mark Forney at: [hope@hopeneuron.com](mailto:hope@hopeneuron.com)**